65,437 trials
Breast Cancer
Primary: Invasive Disease-free Survival (IDFS) Rate at 3 Years — 77.12; 88.44 percentage of participants — p=<0.0001
Corneal Ulcer · Fungal Keratitis
Primary: Culture Positivity at Day 3 Using Potassium Hydroxide (KOH) Wet Mount to Test for Fungus — 14; 11 Participants — p=0.26
Cost Sharing, Acute Coronary Syndrome
Primary: Kaplan-Meier Cumulative Incidence Rate of Major Adverse Cardiovascular Events — 10.17; 10.93 Percentage of Participants — p=0.3503
Cancer Disease Progression
Primary: Inter-observer (B1 and B2) Reproducibility of the PET-CT by Anatomical Regions — 0.7254; 0.7854; 0.7597; 0.6711 Weighted kappa concordance coefficient
Smoking Cessation
Primary: 30-day Abstinence — 168; 237; 302 Participants
Correction of Moderate to Severe Nasolabial Folds
Primary: Mean Pain Using Visual Analog Scale (VAS) — 3.07; 5.94 score on a scale — p=<0.0001
Lymphocytic Leukemia, Chronic
Primary: Progression Free Survival (PFS) Based on Investigator Assessment According to IWCLL Criteria — NA; NA months — p=<0.0001
Psoriasis
Primary: Percentage of Participants Who Achieved a Psoriasis Area and Severity Index (PASI)-90 Response at Week 48 — 84.5; 70.0 Percentage of participants — p=<0.001
Liver Cancer
Primary: Time to Progression (TTP) in Patients Treated With TACE and Y90 — 26; 6.8 Months — p=0.007
Jaw, Edentulous, Partially
Primary: Implant Survival Rate — 93 Implants
Kidney Transplantation
Primary: Number of Participants With Biopsy-proven Acute Rejection at 6-months After Randomization to Induction Therapy — 31; 68 Participants — p=<0.0001
Carcinoma, Non-Small-Cell Lung
Primary: Percentage of Patients With Objective Response (OR) in Part A According to Response Evaluation Criteria in Solid Tumours (RECIST) 1.1 — 0.0 Percentage of participants
Recurrent Adult Hodgkin Lymphoma · Recurrent Childhood Hodgkin Lymphoma · Refractory Childhood Hodgkin Lymphoma
Primary: Maximum Tolerated Dose (MTD) for Brentuximab Vedotin — 1.8 mg/kg
Skin Care
Primary: Number of Participants With a Unit Change of Greater Than (>) 1 in Signs and Symptoms of Cutaneous Irritation Total Scores From Baseline to 21 Days of Product Use — 3; 0…
Sleep
Primary: SleepSure (Questionnaire). A Short Questionnaire of the Quality and Quantity of Sleep, and Use of Aids. — 5.09; 6.33 units on a scale